
SMTI Stock Forecast & Price Target
SMTI Analyst Ratings
Bulls say
Sanara MedTech's sales for surgical soft tissue repair products experienced a significant year-over-year growth of 24%, reaching $23.4 million, largely driven by strong demand for its CellerateRX Surgical Powder and BIASURGE Surgical Solution. The company has shown a strong trajectory for future revenues, with top-line growth projections of 3-5% for 2025 and an anticipated 13-17% growth for 2026, alongside the expected profitability from continuing operations achieved in the third quarter of 2025. Additionally, strategic partnerships, such as the newly secured contract with Vizient, enhance access to Sanara's products and support the company's ongoing efforts to improve operational efficiency and expand its market presence.
Bears say
Sanara MedTech Inc. reported net revenue of $26.3 million, indicating a year-over-year growth of 21.5%, yet this figure fell short of the projected $26.7 million, highlighting potential weaknesses in revenue generation. The company faces several risks, including the possibility of lower-than-expected revenue growth, challenges in acquiring new customers, difficulties in launching new products, and prospects of dilution, which could hinder its overall performance. Additionally, the reduction of the enterprise value to revenue multiple from 4.3x to 3.0x reflects a reevaluation of the company's market position following the exclusion of telehealth from its business strategy.
This aggregate rating is based on analysts' research of Sanara MedTech Inc. and is not a guaranteed prediction by Public.com or investment advice.
SMTI Analyst Forecast & Price Prediction
Start investing in SMTI
Order type
Buy in
Order amount
Est. shares
0 shares